Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 May;37(5):856-862.
doi: 10.1111/dme.14218. Epub 2020 Jan 15.

Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injection therapy: data from the German/Austrian DPV registry

Affiliations
Comparative Study

Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injection therapy: data from the German/Austrian DPV registry

J Grammes et al. Diabet Med. 2020 May.

Abstract

Aim: To compare clinical characteristics and outcomes in adults with type 1 diabetes aged ≥ 60 years using continuous subcutaneous insulin infusion (CSII) vs. insulin injection therapy. Further, to determine the percentage of older adults with type 1 diabetes using CSII.

Research design and methods: Retrospective study using data of the Diabetes Prospective Follow-up Registry (DPV). Including percentage CSII use from 2008 to 2018, and the characteristics of 9547 individuals extracted from the DPV in March 2019 (N = 1404 CSII; N = 8143 insulin injection therapy). Wilcoxon rank sum tests were used for continuous variables and chi-square tests for categorical variables to compare clinical characteristics of people using CSII vs. insulin injection therapy. Adjusted analyses used generalized linear models to compare diabetes-related outcomes.

Results: CSII usage has increased in older adults (from 12% in 2008 to 23% in 2018). After adjustment, CSII was associated with lower HbA1c [60.7 mmol/mol (7.7 ± 0.1%) vs. 62.8% (7.9 ± 0.1%)], lower daily insulin dose (0.49 ± 0.02 vs. 0.61 ± 0.01 IU/kg), fewer days in hospital (8.1 ± 0.12 vs. 11.2 ± 0.11 days/person-year), fewer severe hypoglycaemic events (0.16 ± 0.02 vs. 0.21 ± 0.03 events/person-year) and fewer diabetic ketoacidosis (0.06 ± 0.01 vs. 0.08 ± 0.01 events/person-year). Individuals on CSII showed lower rates of microalbuminuria and also have a diagnosis of depression and neuropathy.

Conclusions: A growing number of older adults are using insulin pumps. Older age in itself should not be seen as a contraindication for CSII.

PubMed Disclaimer

Comment in

References

    1. Lung TW, Hayes AJ, Herman WH, Si L, Palmer AJ, Clarke PM. A meta-analysis of the relative risk of mortality for type 1 diabetes patients compared to the general population: exploring temporal changes in relative mortality. PLoS One 2014; 9: e113635.
    1. Gonder-Frederick LA, Shepard JA, Grabman JH, Ritterband LM. Psychology, technology, and diabetes management. Am Psychol 2016; 71: 577-589.
    1. Karges B, Rosenbauer J, Kapellen T, Wagner VM, Schober E, Karges W et al. Hemoglobin A1c levels and risk of severe hypoglycemia in children and young adults with type 1 diabetes from Germany and Austria: a trend analysis in a cohort of 37,539 patients between 1995 and 2012. PLoS Med 2014; 11: e1001742.
    1. Insulin Pump Market Prospect, Share, Development, Growth and Demand Forecast to 2022, 2017. Available at https://www.researchandmarkets.com/research/qnp7d9/north_america Last accessed 21 November 2019.
    1. Wong JC, Boyle C, DiMeglio LA, Mastrandrea LD, Abel KL, Cengiz E et al. T1D Exchange Clinic Network. Evaluation of pump discontinuation and associated factors in the T1D Exchange Clinic Registry. J Diabetes Sci Technol 2017; 11: 224-232.

Publication types

MeSH terms

LinkOut - more resources